EfficacyHigh
Studies12
Participants450
StatusAvailable
Sermorelin
Sermorelin acetate (GHRH 1-29)
Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
18%
injection site reactions
10%
facial flushing
7%
headache
4%
nausea
6%
fatigue
5%
dizziness
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.